JP5030329B2 - 心臓肥大の処置 - Google Patents

心臓肥大の処置 Download PDF

Info

Publication number
JP5030329B2
JP5030329B2 JP2000542031A JP2000542031A JP5030329B2 JP 5030329 B2 JP5030329 B2 JP 5030329B2 JP 2000542031 A JP2000542031 A JP 2000542031A JP 2000542031 A JP2000542031 A JP 2000542031A JP 5030329 B2 JP5030329 B2 JP 5030329B2
Authority
JP
Japan
Prior art keywords
ifn
cardiac hypertrophy
composition
hypertrophy
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000542031A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002510645A5 (cg-RX-API-DMAC7.html
JP2002510645A (ja
Inventor
ホンクイ ジン,
シェンウィ ル,
ニコラス ジェイ. パオニ,
レンフイ ヤン,
Original Assignee
ジェネンテック, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェネンテック, インコーポレイテッド filed Critical ジェネンテック, インコーポレイテッド
Publication of JP2002510645A publication Critical patent/JP2002510645A/ja
Publication of JP2002510645A5 publication Critical patent/JP2002510645A5/ja
Application granted granted Critical
Publication of JP5030329B2 publication Critical patent/JP5030329B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
JP2000542031A 1998-04-02 1999-03-19 心臓肥大の処置 Expired - Fee Related JP5030329B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8044898P 1998-04-02 1998-04-02
US60/080,448 1998-04-02
PCT/US1999/006032 WO1999051260A2 (en) 1998-04-02 1999-03-19 Treatment of cardiac hypertrophy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009181954A Division JP2009256375A (ja) 1998-04-02 2009-08-04 心臓肥大の処置

Publications (3)

Publication Number Publication Date
JP2002510645A JP2002510645A (ja) 2002-04-09
JP2002510645A5 JP2002510645A5 (cg-RX-API-DMAC7.html) 2006-04-13
JP5030329B2 true JP5030329B2 (ja) 2012-09-19

Family

ID=22157456

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000542031A Expired - Fee Related JP5030329B2 (ja) 1998-04-02 1999-03-19 心臓肥大の処置
JP2009181954A Pending JP2009256375A (ja) 1998-04-02 2009-08-04 心臓肥大の処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009181954A Pending JP2009256375A (ja) 1998-04-02 2009-08-04 心臓肥大の処置

Country Status (17)

Country Link
US (2) US6187304B1 (cg-RX-API-DMAC7.html)
EP (2) EP1067958B1 (cg-RX-API-DMAC7.html)
JP (2) JP5030329B2 (cg-RX-API-DMAC7.html)
CN (1) CN1201814C (cg-RX-API-DMAC7.html)
AR (1) AR018174A1 (cg-RX-API-DMAC7.html)
AT (2) ATE332144T1 (cg-RX-API-DMAC7.html)
AU (1) AU757910B2 (cg-RX-API-DMAC7.html)
BR (1) BR9909422A (cg-RX-API-DMAC7.html)
CA (1) CA2325442C (cg-RX-API-DMAC7.html)
DE (2) DE69939723D1 (cg-RX-API-DMAC7.html)
DK (2) DK1067958T3 (cg-RX-API-DMAC7.html)
ES (2) ES2314786T3 (cg-RX-API-DMAC7.html)
IL (1) IL138812A0 (cg-RX-API-DMAC7.html)
NZ (1) NZ506854A (cg-RX-API-DMAC7.html)
TW (1) TWI243682B (cg-RX-API-DMAC7.html)
WO (1) WO1999051260A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200004854B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020192659A1 (en) * 1997-09-17 2002-12-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
BR9909422A (pt) * 1998-04-02 2001-09-11 Genentech Inc Método para tratamento de hipertrofia cardìaca, método para preparação de composição farmacêutica para o tratamento de hipertrofia cardìaca e seu produto farmacêutico
ATE376837T1 (de) * 1999-07-12 2007-11-15 Genentech Inc Stimulierung oder hemmung von angiogenese und herzvaskularisierung mit tumor nekrose faktor ligand/rezeptor homologen
US7838225B2 (en) * 1999-10-29 2010-11-23 Hologic, Inc. Methods for detection of a target nucleic acid by forming a cleavage structure using a reverse transcriptase
US7625584B2 (en) * 2000-11-30 2009-12-01 The Research Foundation Of State University Of New York Method of complexing a protein by the use of a dispersed system and proteins thereof
US8110218B2 (en) * 2000-11-30 2012-02-07 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic protein-lipid complexes
AU2002310922A1 (en) * 2001-05-04 2002-11-18 Institute Of Molecular And Cell Biology Interferons in the treatment of ischemia
US20050079156A1 (en) * 2001-11-06 2005-04-14 Grace Wong Method of treating endometreosis
WO2003068260A1 (fr) * 2002-02-14 2003-08-21 Chugai Seiyaku Kabushiki Kaisha Produits pharmaceutiques en solution contenant des anticorps
KR101160780B1 (ko) * 2002-08-29 2012-06-27 산텐 세이야꾸 가부시키가이샤 Rho 키나아제 억제제 및 프로스타글란딘류를 포함하는 녹내장 치료제
WO2004045644A1 (ja) * 2002-11-18 2004-06-03 Santen Pharmaceutical Co., Ltd. Rhoキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤
EP1522857A1 (en) * 2003-10-09 2005-04-13 Universiteit Maastricht Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
WO2009154770A2 (en) * 2008-06-18 2009-12-23 The Texas A & M University System Mesenchymal stem cells, compositions, and methods for treatment of cardiac tissue damage
USD647411S1 (en) 2011-01-12 2011-10-25 Rain Bird Corporation Water timer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5096705A (en) 1981-10-19 1992-03-17 Genentech, Inc. Human immune interferon
US5582824A (en) 1981-10-19 1996-12-10 Genentech, Inc. Recombinant DES-CYS-TYR-CYS human immune interferon
AU561343B2 (en) 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
US4929544A (en) 1982-04-23 1990-05-29 Sri International Reagents, methods, and test kit for diagnosing/monitoring cancer in humans
US4855238A (en) 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
US4944941A (en) 1987-08-07 1990-07-31 Genentech, Inc. Methods and compositions for the treatment of lung conditions
US5151265A (en) * 1987-11-03 1992-09-29 Genentech, Inc. Gamma interferon formulation
IL88233A (en) * 1987-11-03 1993-08-18 Genentech Inc Gamma interferon formulation
SE462364B (sv) 1988-09-30 1990-06-18 Goeran Hansson Anvaendning av gamma-interferon foer beredning av ett preparat foer behandling av vaskulaer stenos
DK0502997T3 (da) 1989-12-01 1995-07-17 Childrens Medical Center Behandling af atopiske sygdomme med gamma-interferon
US6207641B1 (en) * 1995-03-10 2001-03-27 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Pharmaceutical composition containing IFN-γ inducing polypeptide or factor for treating and/or preventing IFN-γ susceptive diseases
US5573762A (en) 1995-04-24 1996-11-12 Genentech, Inc. Use of leukemia inhibitory factor specific antibodies and endothelin antagonists for treatment of cardiac hypertrophy
WO1997007820A1 (fr) * 1995-08-30 1997-03-06 Toray Industries, Inc. Remede destine aux maladies cardiaques
BR9909422A (pt) * 1998-04-02 2001-09-11 Genentech Inc Método para tratamento de hipertrofia cardìaca, método para preparação de composição farmacêutica para o tratamento de hipertrofia cardìaca e seu produto farmacêutico

Also Published As

Publication number Publication date
DK1702623T3 (da) 2009-01-19
ES2314786T3 (es) 2009-03-16
EP1702623A3 (en) 2007-01-10
TWI243682B (en) 2005-11-21
AU3102499A (en) 1999-10-25
CN1201814C (zh) 2005-05-18
NZ506854A (en) 2003-07-25
ZA200004854B (en) 2001-09-26
ES2267258T3 (es) 2007-03-01
CA2325442C (en) 2011-10-11
EP1702623B1 (en) 2008-10-08
JP2002510645A (ja) 2002-04-09
EP1067958A2 (en) 2001-01-17
IL138812A0 (en) 2001-10-31
ATE410181T1 (de) 2008-10-15
JP2009256375A (ja) 2009-11-05
EP1702623A2 (en) 2006-09-20
US6187304B1 (en) 2001-02-13
WO1999051260A3 (en) 1999-12-09
EP1067958B1 (en) 2006-07-05
HK1036019A1 (en) 2001-12-21
ATE332144T1 (de) 2006-07-15
US6989364B1 (en) 2006-01-24
HK1099197A1 (en) 2007-08-10
DE69932235T2 (de) 2007-06-14
WO1999051260A2 (en) 1999-10-14
DE69932235D1 (de) 2006-08-17
CN1300221A (zh) 2001-06-20
AU757910B2 (en) 2003-03-13
AR018174A1 (es) 2001-10-31
CA2325442A1 (en) 1999-10-14
DK1067958T3 (da) 2006-11-06
DE69939723D1 (de) 2008-11-20
BR9909422A (pt) 2001-09-11

Similar Documents

Publication Publication Date Title
JP2009256375A (ja) 心臓肥大の処置
Hara et al. Evidence for a role of mast cells in the evolution to congestive heart failure
US20200222516A1 (en) Compositions and Methods for Modulating Cardiac Conditions
US8361966B2 (en) Use of interleukin-11 as therapeutic agent for heart disease
US7261881B1 (en) Modulation of angiogenesis and wound healing
US9084761B2 (en) Use of interleukin-15 to treat cardiovascular diseases
US20080057030A1 (en) Methods of treating idiopathic pulmonary fibrosis
Burbach et al. Interleukin-18 expression and modulation in human corneal epithelial cells
US20070053877A1 (en) Methods of treating idiopathic pulmonary fibrosis
US20100209383A1 (en) Use of g-csf for treating ischemia
HK1099197B (en) Use of interferon gamma for the treatment of cardiac hypertrophy
MXPA00009416A (en) Treatment of cardiac hypertrophy
US7531510B2 (en) Methods of recruiting fibroblasts by administering G-CSF
HK1036019B (en) Treatment of cardiac hypertrophy
Liu et al. Oral supplementation of l-arginine improves ventricular remodeling by regulating angiogenesis and collagen synthesis in myocardial infarction rats
KR20150009656A (ko) 양막 간엽줄기세포를 포함하는 허혈성 질환 치료용 조성물
WO2021198929A1 (en) Anti-il6 agent for treating coronavirus infection
Bekdash et al. IL-33 Induces Type-2-Cytokine Phenotype but Exacerbates Cardiac Remodeling Post-Myocardial Infarction with Eosinophil Recruitment, Worsened Systolic 2 Dysfunction, and Ventricular Wall Rupture 3
KR20150106865A (ko) 양막 간엽줄기세포를 포함하는 허혈성 질환 치료용 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090804

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090831

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20091225

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100309

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20100716

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120501

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120626

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150706

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees